Species-conserved reconfigurations of brain network topology induced by ketamine
- PMID: 27093068
- PMCID: PMC4872411
- DOI: 10.1038/tp.2016.53
Species-conserved reconfigurations of brain network topology induced by ketamine
Abstract
Species-conserved (intermediate) phenotypes that can be quantified and compared across species offer important advantages for translational research and drug discovery. Here, we investigate the utility of network science methods to assess the pharmacological alterations of the large-scale architecture of brain networks in rats and humans. In a double-blind, placebo-controlled, cross-over study in humans and a placebo-controlled two-group study in rats, we demonstrate that the application of ketamine leads to a topological reconfiguration of large-scale brain networks towards less-integrated and more-segregated information processing in both the species. As these alterations are opposed to those commonly observed in patients suffering from depression, they might indicate systems-level correlates of the antidepressant effect of ketamine.
Conflict of interest statement
AM-L received consultance fees from Astra Zeneca, Elsevier, F. Hoffmann-La Roche, Gerson Lehrman Group, Lund-beck foundation, Outcome Europe Sárl, Outcome Sciences, Roche Pharma, Servier International and Thieme Verlag, and lecture fees—including the travel fees—from Abbott, Astra Zeneca, Aula Médica Congresos, BASF, Groupo Ferrer International, Janssen-Cilag, Lilly Deutschland, LVR Klinikum Düsseldorf, Servier Deutschland, Otsuka Pharmaceuticals. AJS is an employee and shareholder of Eli Lilly. ES is a full-time employee of Servier. The remaining authors declare no conflict of interest.
Figures
References
-
- Anticevic A, Corlett PR, Cole MW, Savic A, Gancsos M, Tang Y et al. N-methyl-D-aspartate receptor antagonist effects on prefrontal cortical connectivity better model early than chronic schizophrenia. Biol Psychiatry 2015; 77: 569–580. - PubMed
-
- Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351–354. - PubMed
-
- Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856–864. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
